Jay A. Levy, MD

Jay A. Levy, MD

Professor in Residence, Department of Medicine, UCSF


Phone: (415) 476-4071 (voice)
Box 1270, UCSF
San Francisco, CA 94143-1270

View on UCSF Profiles

Cancer Center Membership

Associate Member » Cancer, Immunity, and Microenvironment


Wesleyan University, Middletown, CT, BA, 1960, Biology
Universite de Paris, France, 1961, Regeneration
Columbia University, New York, MD, 1965, Medicine and Virology

Professional Experience

  • 1965-1966
    Intern in Medicine, Hospital of the University of Pennsylvania
  • 1966-1967
    First year resident in Medicine, Hospital of the University of Pennsylvania
  • 1967-1970
    Staff Associate,National Cancer Institute, NIH, Bethesda, MD
  • 1970-1971
    Second year resident, University of California, San Francisco (UCSF)
  • 1971-1972
    Visiting Scientist, Hopital St. Louis (Prof. M. Boiron), Paris; Hopital Paul-Brousse (Dr. G. Mathe), ICIG, Paris
  • 1972-1977
    Assistant Professor of Medicine, Research Associate, Cancer Research Institute, University of California San Francisco
  • 1978-1979
    Visiting Scientist, Weizmann Institute, Rehovot, Israel (Prof. N. Haran-Ghera); Pasteur Institute, Paris (Prof. F. Jacob)
  • 1978-1985
    Associate Professor of Medicine, and Microbiology and Immunology, University of California San Francisco
  • 1985-present
    Professor, Dept of Med., Div of Hem/Onc and Research Assoc, Cancer Research Institute, UCSF

Selected Publications

  1. AIDS new editor announcement. AIDS. 2016 Jan; 30(2):165.
    View on PubMed
  2. Discovery of another anti-HIV protein in the search for the CD8+ cell anti-HIV Factor. Proc Natl Acad Sci U S A. 2015 Jun 30; 112(26):7888-9.
    View on PubMed
  3. Conserved epitopes on HIV-1, FIV and SIV p24 proteins are recognized by HIV-1 infected subjects. Hum Vaccin Immunother. 2015 Jun 3; 11(6):1540-56.
    View on PubMed
  4. Dispelling myths and focusing on notable concepts in HIV pathogenesis. Trends Mol Med. 2015 Jun; 21(6):341-53.
    View on PubMed
  5. Seamless modification of wild-type induced pluripotent stem cells to the natural CCR5?32 mutation confers resistance to HIV infection. Proc Natl Acad Sci U S A. 2014 Jul 1; 111(26):9591-6.
    View on PubMed
  6. Chemically modified peptides based on the membrane-proximal external region of the HIV-1 envelope induce high-titer, epitope-specific nonneutralizing antibodies in rabbits. Clin Vaccine Immunol. 2014 Aug; 21(8):1086-93.
    View on PubMed
  7. Evolutionarily conserved epitopes on human immunodeficiency virus type 1 (HIV-1) and feline immunodeficiency virus reverse transcriptases detected by HIV-1-infected subjects. J Virol. 2013 Sep; 87(18):10004-15.
    View on PubMed
  8. Nevirapine inhibits the anti-HIV activity of CD8+ cells. J Acquir Immune Defic Syndr. 2013 Jun 1; 63(2):184-8.
    View on PubMed
  9. Plasmacytoid dendritic cell number and responses to Toll-like receptor 7 and 9 agonists vary in HIV Type 1-infected individuals in relation to clinical state. AIDS Res Hum Retroviruses. 2013 Mar; 29(3):501-10.
    View on PubMed
  10. AIDS and HIV Infection after Thirty Years. AIDS Res Treat. 2013; 2013:731983.
    View on PubMed
  11. HIV-1 Vaccine Trials: Evolving Concepts and Designs. Open AIDS J. 2012; 6:274-88.
    View on PubMed
  12. HIV infection: what should be considered in approaches for a cure? AIDS. 2012 Nov 13; 26(17):2253-5.
    View on PubMed
  13. HIV-related symptoms and patient clusters among Chileans living with HIV. AIDS Care. 2013; 25(4):488-95.
    View on PubMed
  14. 25 Years of AIDS: recording progress and future challenges. AIDS. 2012 Jun 19; 26(10):1187-9.
    View on PubMed
  15. Differential transmission of HIV traversing fetal oral/intestinal epithelia and adult oral epithelia. J Virol. 2012 Mar; 86(5):2556-70.
    View on PubMed
  16. HIV/AIDS: 30 years of progress and future challenges. Eur J Immunol. 2011 Dec; 41(12):3401-11.
    View on PubMed
  17. Transfection optimization for primary human CD8+ cells. J Immunol Methods. 2011 Sep 30; 372(1-2):22-9.
    View on PubMed
  18. No evidence of murine-like gammaretroviruses in CFS patients previously identified as XMRV-infected. Science. 2011 Jul 1; 333(6038):94-7.
    View on PubMed
  19. Virus-host interactions in HIV pathogenesis: directions for therapy. Adv Dent Res. 2011 Apr; 23(1):13-8.
    View on PubMed
  20. Sex, race, and geographic region influence clinical outcomes following primary HIV-1 infection. J Infect Dis. 2011 Feb 15; 203(4):442-51.
    View on PubMed

Go to UCSF Profiles, powered by CTSI